company background image
APPH

Apontis Pharma DB:APPH Stock Report

Last Price

€13.30

Market Cap

€113.1m

7D

-5.0%

1Y

-24.9%

Updated

20 May, 2022

Data

Company Financials +
APPH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

APPH Stock Overview

Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany.

Apontis Pharma Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Apontis Pharma
Historical stock prices
Current Share Price€13.30
52 Week High€27.30
52 Week Low€10.60
Beta0
1 Month Change3.91%
3 Month Change-16.88%
1 Year Change-24.86%
3 Year Changen/a
5 Year Changen/a
Change since IPO-29.44%

Recent News & Updates

Shareholder Returns

APPHDE PharmaceuticalsDE Market
7D-5.0%5.6%-0.1%
1Y-24.9%14.2%-12.9%

Return vs Industry: APPH underperformed the German Pharmaceuticals industry which returned 12.5% over the past year.

Return vs Market: APPH underperformed the German Market which returned -13.3% over the past year.

Price Volatility

Is APPH's price volatile compared to industry and market?
APPH volatility
APPH Average Weekly Movement8.8%
Pharmaceuticals Industry Average Movement6.7%
Market Average Movement6.3%
10% most volatile stocks in DE Market10.7%
10% least volatile stocks in DE Market3.5%

Stable Share Price: APPH is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: APPH's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a148Karlheinz Gasthttps://apontis-pharma.de

Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company is headquartered in Monheim am Rhein, Germany.

Apontis Pharma Fundamentals Summary

How do Apontis Pharma's earnings and revenue compare to its market cap?
APPH fundamental statistics
Market Cap€113.05m
Earnings (TTM)-€745.24k
Revenue (TTM)€51.18m

2.2x

P/S Ratio

-151.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
APPH income statement (TTM)
Revenue€51.18m
Cost of Revenue€17.40m
Gross Profit€33.79m
Other Expenses€34.53m
Earnings-€745.24k

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.088
Gross Margin66.01%
Net Profit Margin-1.46%
Debt/Equity Ratio0.0%

How did APPH perform over the long term?

See historical performance and comparison

Valuation

Is Apontis Pharma undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: APPH (€13.3) is trading below our estimate of fair value (€127.81)

Significantly Below Fair Value: APPH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: APPH is unprofitable, so we can't compare its PE Ratio to the German Pharmaceuticals industry average.

PE vs Market: APPH is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate APPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APPH is overvalued based on its PB Ratio (2.8x) compared to the DE Pharmaceuticals industry average (2.6x).


Future Growth

How is Apontis Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


46.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.05%).

Earnings vs Market: APPH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: APPH's is expected to become profitable in the next 3 years.

Revenue vs Market: APPH's revenue (15.9% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: APPH's revenue (15.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: APPH's Return on Equity is forecast to be low in 3 years time (13.9%).


Past Performance

How has Apontis Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


37.0%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: APPH is currently unprofitable.

Growing Profit Margin: APPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if APPH's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare APPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.1%).


Return on Equity

High ROE: APPH has a negative Return on Equity (-1.83%), as it is currently unprofitable.


Financial Health

How is Apontis Pharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: APPH's short term assets (€38.0M) exceed its short term liabilities (€10.0M).

Long Term Liabilities: APPH's short term assets (€38.0M) exceed its long term liabilities (€3.4M).


Debt to Equity History and Analysis

Debt Level: APPH is debt free.

Reducing Debt: APPH had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable APPH has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: APPH is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 66.2% per year.


Dividend

What is Apontis Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate APPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APPH's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as APPH has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Karlheinz Gast

no data

Tenure

Mr. Karlheinz Gast serves as Chief Executive Officer at Apontis Pharma AG and serves as Chairman of the Management Board. He is active in the industry since 1986 and holding the following company positions...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Apontis Pharma AG's employee growth, exchange listings and data sources


Key Information

  • Name: Apontis Pharma AG
  • Ticker: APPH
  • Exchange: DB
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €113.050m
  • Shares outstanding: 8.50m
  • Website: https://apontis-pharma.de

Number of Employees


Location

  • Apontis Pharma AG
  • Alfred-Nobel-Str. 10
  • Monheim am Rhein
  • North Rhine-Westphalia
  • 40789
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/20 00:00
End of Day Share Price2022/05/19 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.